Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug. Issue 1 (27th July 2020)

• Record Type: Journal Article
• Authors: Tobi, Allan; Willmore, Anne‐Mari A.; Kilk, Kalle; Sidorenko, Valeria; Braun, Gary B.; Soomets, Ursel; Sugahara, Kazuki N.; Ruoslahti, Erkki; Teesalu, Tambet
• Is Part Of: Advanced therapeutics. Volume 4:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-27
• Subjects: homing peptides -- monomethyl auristatin e -- neuropilin‐1 -- silver nanoparticles -- C‐end Rule; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202000097
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Silver nanoparticles (AgNP) can be tracked in cells and tissues by optical imaging and isotopic fingerprinting. AgNPs are particularly useful as endocytosis probes as they can be rapidly dissolved with a biocompatible etching solution to eliminate extracellular NPs.Here, affinity‐targeted AgNPs are evaluated as therapeutic carriers of a potent cytotoxic compound, monomethyl auristatin E (MMAE). AgNPs are coated with MMAE via a lysosomal protease cathepsin B sensitive linker and functionalized with a prototypic CendR peptide (RPARPAR) that targets neuropilin‐1 (NRP‐1). This gives the AgNPs dual tumor specificity as both cathepsin B and NRP‐1 are overexpressed in many types of solid tumors. Cellular imaging, flow cytometry, viability assays, and high‐performance liquid chromatography‐mass spectrometry (HPLC‐MS) analysis show that the RPARPAR–MMAE–AgNPs are internalized and induce apoptotic cell death in NRP‐1‐positive PPC‐1 prostate cancer cells while sparing NRP‐1‐negative M21 melanoma cells. Furthermore, in a mixed culture of PPC‐1 and M21 cells, RPARPAR–MMAE–AgNP treatment selectively eliminates NRP‐1‐positive PPC‐1 cells. The study demonstrates that affinity‐targeted AgNPs can be used as carriers to selectively deliver and potentiate the activity of cytotoxic compounds in vitro, and that treatment with a biocompatible etching solution can be used to control the internalization and, thus, the cytotoxicity of these AgNPs. Abstract : Silver nanoparticles (AgNP) with a targeting peptide (RPARPAR) and a cytotoxic payload monomethyl auristatin E (MMAE) bind to neuropilin‐1 (NRP‐1) on the surface of target cancer cells, initiating endocytosis. In lysosomes, the active form of tubulin‐binding MMAE is released via specific cleavage by cathepsin B (Cat B), causing cell death, and extracellular AgNPs can be removed with a biocompatible etching solution.